479. Ten Year Evaluation and Therapeutic Efficacy of Three Different Regimens in Naive Children with Chronic Hepatitis B Infection
Session: Poster Abstract Session: Pediatric Viral Infections
Thursday, October 8, 2015
Room: Poster Hall
Background: The aim of the present study was to evaluate naïve children with chronic hepatitis B (CHB) infection and to compare the therapeutic efficacy of  three different regimens in this patients groups.

Methods: In this retrospective study,  403  naive  children with chronic hepatitis B (CHB)  infection  who had been  followed-up  at the out-patient pediatric infectious disease clinics of  Balcali Hospital from 2004 January  to 2013 December  were evaluated. Of the total 403 pediatric patients who had CHB infection, while 126 ( 31,2 % )  had spontanenous seroconversion, 277(68.8%) did not have spontanenous seroconversion. Of the total 277 pediatric patients who had CHB infection,  165 ( 40,9% ) were treated with three  different treatment modalities, 112 ( 27,8% ) had been followed-up with CHB infection. A total of 165 children were prospectively allocated  to three  treatment groups i.e. monotherapy (group I and group II) and combination therapy (group III). In the monotherapy groups; group 1; 35  patients received interferon-alpha  (IFN-α) 2b, for 6 months, group II: 29 patients received Lamuvidin (LAM) for 12 months. In the combination groups; 101  patients in the Group III received LAM for 12 months and  IFN-α 2b  added to LAM for first 6 months.

Results: The median age of 403 patients who participated in the study  was 192 months and the median diagnosis period was 119 months. 57,1% of the patients were identified during family screening. The existence of hepatitis B in the family was 82,6%. When the patients who had spontaneous seroconversion and those who had no spontaneous seroconversion are examined, it is seen that the median age (198 months) and median diagnosis period (122 months) in the patients with spontenous seroconversion was statistically higher and longer than those without spontenous seroconversion (190 vs 108, respectively) (p<0.01). No statistically significant difference was found in terms of response to treatment between the three different treatment modalities.

Conclusion: In this study, no statistically significant difference was found in terms of response to treatment between the three different treatment modalities given to the patients who met treatment criteria. The potential benefits of  these three  theuropatic regimens need to be futher investigated  to confirm these results with larger number of patients.

 

Emine Kocabas, Prof (MD)1, Ergin Cucu, MD2, Ummuhan Cay, MD1, Gulsah Seydaoglu, Prof (MD)3, Akgun Yaman, Prof (MD)4 and Emre Alhan, Prof (MD)1, (1)Pediatric Infectious Diseases, Cukurova University, Adana, Turkey, (2)Pediatrics, Cukurova University, Adana, Turkey, (3)Biostatistics, Cukurova University, Adana, Turkey, (4)Microbiology, Cukurova University, Adana, Turkey

Disclosures:

E. Kocabas, None

E. Cucu, None

U. Cay, None

G. Seydaoglu, None

A. Yaman, None

E. Alhan, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.